cevostamab
roche
['bet', 'cevostamab']
cevostamab is the first bispecific to show durable results with fixed duration rather than continuous therapy. median dor is 11.1 months with median time on therapy 8.8 months. infections are the achilles heel of bispecifics. so longer intervals between doses is key! #ash22 
Multiple Myeloma Oncologist